Editas Medicine (NASDAQ:EDIT) 报告季度每股亏损$0.55，低于分析师普遍预期的$0.38，相差44.74%。与去年同期每股亏损$0.23相比，这是一个139.13%的下降。公司报告季度销售额为$30.604百万，低于分析师普遍预期的$32.230百万，相差5.04%。与去年同期的$60.050百万相比，这是一个49.04%的下降。
以上内容来自Benzinga Earnings专栏，原文如下：
Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.38) by 44.74 percent. This is a 139.13 percent decrease over losses of $(0.23) per share from the same period last year. The company reported quarterly sales of $30.604 million which missed the analyst consensus estimate of $32.230 million by 5.04 percent. This is a 49.04 percent decrease over sales of $60.050 million the same period last year.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。